S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Committee pitches concept to settle all opioid lawsuits

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

A committee guiding OxyContin maker Purdue Pharma's bankruptcy has suggested other drugmakers, distributors and pharmacy chains use Purdue's bankruptcy proceedings to settle more than 2,000 lawsuits seeking to hold the drug industry accountable for the national opioid crisis.

The committee of unsecured creditors said in a letter sent Sunday to the parties and obtained by The Associated Press that the country "is in the grips of a crisis that must be addressed, and that doing so may require creative approaches."

It's calling for all the companies to put money into a fund in exchange for having all their lawsuits resolved.

The committee includes victims of the opioid crisis plus a medical center, a health insurer, a prescription benefit management company, the manufacturer of an addiction treatment drug and a pension insurer. It says that the concept may not be feasible but invited further discussion. It does not give a size of contributions from the company.

The same committee has been aggressive in Purdue's bankruptcy, saying it would support pausing litigation against members of the Sackler family who own Purdue in exchange for a $200 million fund from the company to help fight the opioid crisis.

Paul Hanly, a lead lawyer for local governments in the lawsuits, said in a text message Sunday evening that he'd heard about the mass settlement idea, calling it "most unlikely."

The proposal comes as narrower talks have not resulted in a settlement. Opening statements are to be held Monday in the first federal trial over the crisis. The lawsuit deals with claims from the Ohio counties of Cuyahoga and Summit against a half-dozen companies. More than 2,000 other state and local governments plus Native American tribes, hospitals and other groups have made similar claims.

There have been talks aimed at settling all claims against the drugmakers Johnson & Johnson and Teva and the distributors AmerisourceBergen, Cardinal Health and McKesson ahead of the trial. One proposal called for resolving claims against them nationally in exchange for cash and addiction treatment drugs valued at a total of $48 billion over time.


The committee's proposal went to those five companies plus nine others that face lawsuits.

Opioids, including both prescription painkillers and illegal drugs such as heroin and illicitly made fentanyl, have been linked to more than 400,000 deaths in the U.S. since 2000.

___

Associated Press reporter Carla K. Johnson in Seattle contributed to this article.

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Should you invest $1,000 in Cardinal Health right now?

Before you consider Cardinal Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.

While Cardinal Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Cardinal Health (CAH)
4.3342 of 5 stars
$106.00-0.5%1.89%41.73Moderate Buy$103.07
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Search Headlines: